Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Melanoma patients get to pick: shot or IV for their meds?

NCT ID NCT06101134

Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This study looks at whether people with melanoma prefer getting their cancer medicine as a shot under the skin or through an IV. About 100 patients will try both ways and say which they like better. The goal is to make treatment more convenient and comfortable for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have either metastatic melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with surgery no later than 12 weeks before the start of treatment and confirmed free of disease * Must have a low level of disability and cancer that is considered advanced for metastatic melanoma and at risk for becoming advanced (intermediate) or advanced for resected melanoma Exclusion Criteria: * Must not have any brain cancer/disease treated with radiation, any cancer in the eyes or mucous membranes (cells that cover inside surface of parts of the body and keep it moist), any autoimmune disease, or any condition that is being treated with steroids for inflammation (corticosteroids) or medication to decrease the body's immune system response (immunosuppressive drugs) Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma Neoplasm Metastasis Patient Preference

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma

Contacts and locations

Locations

  • Local Institution - 0003

    San Pedro Alcántara, Málaga, 10002, Spain

  • Local Institution - 0004

    Torino, TO, 10126, Italy

  • Local Institution - 0005

    Concepción, 4070196, Chile

  • Local Institution - 0006

    Seville, 41013, Spain

  • Local Institution - 0007

    Anchorage, Alaska, 99508-2974, United States

  • Local Institution - 0008

    Piraeus, 185 47, Greece

  • Local Institution - 0009

    Cartagena, MU, 30120, Spain

  • Local Institution - 0010

    San Francisco, California, 94115-3010, United States

  • Local Institution - 0011

    Barcelona, B, 08025, Spain

  • Local Institution - 0012

    Padova, PD, 35128, Italy

  • Local Institution - 0013

    Phoenix, Arizona, 85054-4502, United States

  • Local Institution - 0014

    Athens, I, 115 27, Greece

  • Local Institution - 0015

    Las Condes, Santiago Metropolitan, 8331010, Chile

  • Local Institution - 0017

    Bergamo, BG, 24127, Italy

  • Local Institution - 0018

    Milan, MI, 20141, Italy

  • Local Institution - 0019

    Thessaloniki, B, 546 22, Greece

  • Local Institution - 0020

    Badalona, 08916, Spain

  • Local Institution - 0021

    Roma, RM, 00144, Italy

  • Local Institution - 0022

    Barcelona, B, 08908, Spain

  • Local Institution - 0023

    Holargos, Athens, 155 62, Greece

  • Local Institution - 0026

    Naples, 80131, Italy

  • Local Institution - 0027

    Cantabria, 39008, Spain

  • Local Institution - 0028

    Albuquerque, New Mexico, 87106, United States

  • Local Institution - 0029

    Marousi, I, 151 25, Greece

  • Local Institution - 0030

    Seattle, Washington, 98104, United States

  • Local Institution - 0032

    Edgewood, Kentucky, 41017, United States

  • Local Institution - 0033

    Thessaloniki, 564 29, Greece

  • Local Institution - 0034

    Atlanta, Georgia, 30342, United States

  • Local Institution - 0035

    Meldola, FC, 47014, Italy

  • Local Institution - 0036

    Issaquah, Washington, 98026, United States

  • Local Institution - 0037

    Edmonds, Washington, 98026-8032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.